Publication

Prenatal screening for trisomy 21 (Down syndrome) using first- and second-trimester biochemistry and nuchal translucency: A technical standard of the American College of Medical Genetics and Genomics (ACMG)

Aug 6, 2025 · 7 authors · 3 topics

Abstract

This technical standard was developed as a guide for laboratories performing prenatal screening for Down syndrome. It addresses 3 topics: second trimester (triple or quad), first trimester, including incorporation of nuchal translucency, and current directions in cell-free DNA screening. Analytic methods, clinical considerations, screening performance, guidelines for reporting second trimester, first trimester, integrated, contingent, and reflex screening tests for Down syndrome, are discussed. Individual laboratories are responsible for meeting the quality assurance standards described by the Clinical Laboratory Improvement Amendments, the College of American Pathologists, and other regulatory agencies, with respect to appropriate sample documentation, assay validation, general proficiency, and quality control measures. Disclaimer: This technical standard is designed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to this technical standard is voluntary and does not necessarily assure a successful medical outcome. This technical standard should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, clinical laboratory geneticists should apply their own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document the rationale for how a particular test was designed, its intended use and its performance specifications, as well as whether or not it is in conformance with this technical standard. They also are advised to take notice of the date any particular technical standard was adopted and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures. Where individual authors are listed, the views expressed may not reflect those of authors' employers or affiliated institutions.

Showing the abstract — retrieve the full paper via the Exa API.

Authors

Glenn E. PalomakiWendy E. SmithKomal BajajRoss A. RowseyAnna C.E. HurstGeralyn M. Lambert-MesserlianRobert G. Best

Topics

Prenatal Screening and DiagnosticsParvovirus B19 Infection StudiesCongenital Anomalies and Fetal Surgery

About

PublishedAug 6, 2025
TypeArticle
Citations3
References97

Powered by the Exa API